Definium Therapeutics (DFTX) Financials: Revenue & Earnings

DFTX price $38.18 +1.10 +2.97%

Ticker
DFTX
Price
$38.18
Change
+1.10 +2.97%
Market cap ?
$5.13B
P/E ?
-10.78
Forward P/E ?
34.65
Dividend yield ?
0.00%
Beta ?
2.19
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
70
Value
58
Quality
51
Growth
100

Stocklytics score rationale: value 58, quality 51, growth 100.

Financials

2016201720182019202020212022202320242025
0000000000

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another…

Fair value

DFTX fair value $43.11. Price $38.18. Price is 11% below fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Compare DFTX

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-05—-0.56——
2026-08-06-1.44-0.54——
2026-05-07-0.71-0.47——
2026-02-26-0.51-0.48——
2025-11-06-0.78-0.52——
2025-07-31-0.50-0.38——
2025-05-08-0.35-0.36——
2025-03-06-0.41-0.33——
2024-11-07-0.27-0.28——
2024-08-13-0.48-0.30——
2024-05-08-1.14-0.66——
2024-02-28-0.59-0.484.84M—
2023-11-02-0.53-0.65——
2023-08-03-0.72-0.54——
2023-05-04-0.51-0.41——
2023-03-09-0.27-0.49——
2022-11-10-0.56-0.58——
2022-08-11-0.60-0.75——
2022-05-16-0.60-0.75——
2022-03-28-0.75-0.70——
2021-11-12-0.90-0.52——
2021-08-12-1.35-0.60——
2021-05-14-0.57———
2020-12-31-0.48———
2020-11-14-0.45-0.45——
2020-08-13-0.03———
2020-05-14-0.52———
2019-09-30-0.08———
2019-05-31-0.41———
2019-02-28-0.47———
2018-11-30-0.36———
2018-08-31-0.62———
2018-05-31-1.51———
2018-02-28-0.78———
2017-11-30-0.53———
2017-08-31-1.67———
2017-05-31-1.75———
2017-02-28-1.35———
2016-11-30-2.05———

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-09-25Karlin DanielSell10.85K$36.57396.89K
2026-09-25Barrow RobertSell31.55K$36.571.15M
2026-09-25Wiley Matthew T.Sell3.10K$36.57113.26K
2026-09-25Sullivan MarkSell14.05K$36.57513.85K
2026-09-25Roberts BrandiSell3.38K$36.57123.50K
2026-09-18Vallone Carol ABuy1.09K$35.5238.57K
2026-09-18Vallone Carol ASell1.09K$35.5238.57K
2026-09-18Krebs AndreasBuy1.63K$35.5257.86K
2026-09-18Krebs AndreasSell1.63K$35.5257.86K
2026-09-14Karlin DanielBuy200.00K——
2026-09-14Wiley Matthew T.Buy125.00K——
2026-09-14Sullivan MarkBuy125.00K——
2026-09-14Roberts BrandiBuy125.00K——
2026-09-14Barrow RobertBuy750.00K——
2026-09-03Barrow RobertSell19.02K$37.94721.73K
2026-09-02Barrow RobertBuy40.00K——
2026-08-12Barrow RobertBuy375.00K——
2026-08-12Karlin DanielBuy100.00K——
2026-08-12Sullivan MarkBuy62.50K——
2026-08-12Wiley Matthew T.Buy62.50K——
2026-08-12Roberts BrandiBuy62.50K——
2026-06-25Sullivan MarkSell13.01K$45.03585.75K
2026-06-25Roberts BrandiSell3.01K$45.03135.68K
2026-06-25Barrow RobertSell29.21K$45.031.32M
2026-06-25Karlin DanielSell10.04K$45.03451.88K
2026-06-25Wiley Matthew T.Sell2.87K$45.03129.10K
2026-06-22Wiley Matthew T.Buy62.50K——
2026-06-22Barrow RobertBuy375.00K——
2026-06-22Sullivan MarkBuy62.50K——
2026-06-22Roberts BrandiBuy62.50K——
2026-06-22Karlin DanielBuy100.00K——
2026-06-11CRYSTAL ROGERBuy4.67K——
2026-06-11CRYSTAL ROGERBuy19.19K$24.11462.62K
2026-06-11GRYSKA DAVID WBuy4.67K——
2026-06-11GRYSKA DAVID WBuy19.19K$24.11462.62K
2026-06-11Vallone Carol ABuy4.67K——
2026-06-11Vallone Carol ABuy19.19K$24.11462.62K
2026-06-11Krebs AndreasBuy4.67K——
2026-06-11Krebs AndreasBuy19.19K$24.11462.62K
2026-06-11Adsett RogerBuy14.62K$24.11352.49K
2026-06-11Adsett RogerBuy3.56K——
2026-06-11Bruhn Suzanne LouiseBuy4.67K——
2026-06-11Bruhn Suzanne LouiseBuy19.19K$24.11462.62K
2026-03-25Karlin DanielSell8.02K$18.47148.09K
2026-03-25Sullivan MarkSell10.70K$18.47197.67K
2026-03-25Barrow RobertSell24.43K$18.47451.24K
2026-02-03Wiley Matthew T.Buy115.00K——
2026-02-03Roberts BrandiBuy150.00K——
2026-02-03Sullivan MarkBuy125.00K——
2026-02-03Karlin DanielBuy150.00K——
2026-02-03Barrow RobertBuy320.00K——
2026-01-29Adsett RogerBuy50.00K$17.24862.00K
2026-01-29Adsett RogerOther0——
2025-12-26Karlin DanielSell5.60K$13.1573.62K
2025-12-26Barrow RobertSell25.79K$13.15339.07K
2025-12-26Sullivan MarkSell11.28K$13.15148.24K
2025-09-25Sullivan MarkSell11.28K$9.77110.19K
2025-09-25Barrow RobertSell25.80K$9.77252.04K
2025-09-25Karlin DanielSell7.70K$9.7775.27K
2025-06-25Sullivan MarkSell11.49K$6.8078.14K
2025-06-25Karlin DanielSell7.85K$6.8053.37K
2025-06-25Barrow RobertSell26.49K$6.80180.14K
2025-06-12Krebs AndreasBuy75.19K$7.30548.87K
2025-06-12Vallone Carol ABuy75.19K$7.30548.87K
2025-06-12Bruhn Suzanne LouiseBuy75.19K$7.30548.87K
2025-06-12CRYSTAL ROGERBuy75.19K$7.30548.87K
2025-06-12GRYSKA DAVID WBuy75.19K$7.30548.87K
2025-06-02Roberts BrandiBuy500.00K$7.263.63M
2025-06-02Roberts BrandiOther0——
2025-03-25Barrow RobertSell21.21K$6.74142.94K
2025-03-25Karlin DanielSell6.84K$6.7446.07K
2025-03-25Sullivan MarkSell6.58K$6.7444.32K
2025-03-25Liao CarrieSell2.35K$6.7415.82K
2025-03-17Wiley Matthew T.Buy350.00K$6.352.22M
2025-03-17Wiley Matthew T.Other0——
2025-03-12Barrow RobertBuy350.00K——
2025-03-12Karlin DanielBuy115.00K——
2025-03-12Sullivan MarkBuy150.00K——
2025-03-12Liao CarrieBuy50.00K——
2024-12-26Barrow RobertSell19.11K$7.43141.96K
2024-12-26Liao CarrieSell2.27K$7.4316.89K
2024-12-26Karlin DanSell6.64K$7.4349.36K
2024-12-26Sullivan MarkSell4.52K$7.4333.58K
2024-12-05GRYSKA DAVID WBuy2.50K$7.1717.93K
2024-09-25Liao CarrieSell2.35K$5.9814.06K
2024-09-25Barrow RobertSell19.77K$5.98118.23K
2024-09-25Karlin DanSell6.87K$5.9841.09K
2024-09-25Sullivan MarkSell4.43K$5.9826.49K
2024-08-23GRYSKA DAVID WBuy3.50K$5.9820.93K
2024-08-21Halperin Wernli MiriBuy50.00K$3.70185.00K
2024-08-21Halperin Wernli MiriSell32.59K$6.17201.11K
2024-08-21Halperin Wernli MiriSell50.00K$3.70185.00K
2024-08-20Barrow RobertBuy500$6.123.06K
2024-08-19Barrow RobertBuy500$6.313.15K
2024-06-25Karlin DanSell6.92K$7.2250.00K
2024-06-25Barrow RobertSell15.66K$7.22113.06K
2024-06-25Sullivan MarkSell17.85K$7.22128.91K
2024-06-10Vallone Carol ABuy16.51K$7.25119.67K
2024-06-10GRYSKA DAVID WBuy16.51K$7.25119.67K
2024-06-10CRYSTAL ROGERBuy16.51K$7.25119.67K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 389, holders +128 vs prior quarter. Ownership 104.72%.

HolderSharesChangeChange %Value
BLACKROCK, INC.11.23M2.75M+32.46%528.39M
AVORO CAPITAL ADVISORS LLC7.19M2.19M+43.78%338.17M
DRIEHAUS CAPITAL MANAGEMENT LLC6.85M933.39K+15.79%322.00M
JUPITER TOPCO LLC5.62M5.62MNew264.00M
CAPITAL WORLD INVESTORS5.37M5.37MNew252.50M
FMR LLC4.75M2.94M+162.65%223.58M
PRICE T ROWE ASSOCIATES INC /MD/4.65M4.58M+6545.67%218.83M
GEODE CAPITAL MANAGEMENT, LLC3.64M1.15M+46.06%171.48M
STATE STREET CORP3.07M593.52K+24.01%144.20M
CAPITAL INTERNATIONAL INVESTORS2.96M2.96MNew139.40M
OCTAGON CAPITAL ADVISORS LP2.95M510.00K+20.90%138.77M
WELLINGTON MANAGEMENT GROUP LLP2.95M1.64M+126.08%138.76M
DEEP TRACK CAPITAL, LP2.75M-250.00K-8.33%129.36M
COMMODORE CAPITAL LP2.00M00.00%94.08M
GOLDMAN SACHS GROUP INC1.80M125.44K+7.49%84.71M
CITADEL ADVISORS LLC1.69M1.62M+2308.83%79.43M
VANGUARD PORTFOLIO MANAGEMENT LLC1.65M775.76K+88.90%77.54M
RA CAPITAL MANAGEMENT, L.P.1.50M1.50MNew70.56M
VANGUARD CAPITAL MANAGEMENT LLC1.49M389.48K+35.50%69.92M
SIREN, L.L.C.1.42M500.00K+54.38%66.77M
SUSQUEHANNA INTERNATIONAL GROUP, LLP1.39M1.30M+1602.02%65.22M
MARSHALL WACE, LLP1.30M98.12K+8.17%61.10M
NORTHERN TRUST CORP1.17M370.25K+46.34%55.00M
AMERIPRISE FINANCIAL INC1.15M181.75K+18.80%54.02M
NUVEEN, LLC1.11M407.18K+58.32%51.99M

Earnings and financials

Definium Therapeutics, Inc. (DFTX) trades at $38.18, with a market cap of $5.13B and a trailing P/E of -10.78. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

2016201720182019202020212022202320242025
0000000000

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Definium Therapeutics (DFTX) Financials: Revenue & Earnings

DFTX$38.18+1.10 +2.97%

$5.13B

Market Cap

-10.78

P/E

34.65

Forward P/E

70

Score

Price History